Falkai, Peter Gaston

[["dc.bibliographiccitation.firstpage","89"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Revista de psiquiatria clínica"],["dc.bibliographiccitation.lastpage","96"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Schmitt, Andrea"],["dc.contributor.author","Otto, Sylvia"],["dc.contributor.author","Jatzko, Alexander"],["dc.contributor.author","Ruf, Matthias"],["dc.contributor.author","Demirakca, Traute"],["dc.contributor.author","Tost, Heike"],["dc.contributor.author","Gruber, Oliver"],["dc.contributor.author","Parlapani, Eleni"],["dc.contributor.author","Falkai, Peter"],["dc.contributor.author","Braus, Dieter F."],["dc.date.accessioned","2018-11-07T08:35:29Z"],["dc.date.available","2018-11-07T08:35:29Z"],["dc.date.issued","2009"],["dc.description.abstract","Objectives: In first-episode schizophrenia patients, functional magnetic resonance imaging (fMRI) has shown prefronto-parietal dysfunction during acoustic and visual stimulation. The aim of this study was to investigate the prefronto-parietal network in elderly schizophrenia patients using the same paradigm. Additionally, we hypothesized favourable effects on brain activation by the atypical antipsychotic clozapine compared to typical neuroleptics. Methods: We investigated 18 elderly, chronic schizophrenia patients and 21 elderly healthy controls. Nine schizophrenia patients had been medicated with clozapine and 9 had been receiving typical neuroleptics over decades. In addition to assessments with psychopathological and neuropsychological rating scales we used an acoustic and visual stimulation paradigm in a 1.5 Tesla MRI scanner to investigate BOLD-response in different brain areas. Results: Compared to healthy controls schizophrenia patients showed decreased brain activation in the prefrontal and parietal cortex as well as medial anterior cingulate gyrus compared to healthy controls. In these regions, patients medicated with clozapine showed increased BOLD-response compared to patients treated with typical neuroleptics. Discussion: Our study confirmed prefronto-parietal network disturbances in elderly schizophrenia patients thus pointing to the preservation of brain activation deficits and the influence of neurodevelopmental disturbances in chronic schizophrenia until old-age. Conclusion: The atypical antipsychotic clozapine seems to facilitate brain activation even in elderly, chronic schizophrenia patients."],["dc.identifier.doi","10.1590/S0101-60832009000300002"],["dc.identifier.fs","548703"],["dc.identifier.isi","000269276800002"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5793"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18078"],["dc.language.iso","es"],["dc.notes.intern","Migrated from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Univ Sao Paulo, Inst Psiquiatria"],["dc.relation.issn","0101-6083"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","Goescholar"],["dc.rights.access","openAccess"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Parieto-prefrontal dysfunction during visuo-auditory information processing in elderly, chronic schizophrenic patients and medication effects"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","72"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal für Neuologie, Neurochirurgie und Psychiatrie"],["dc.bibliographiccitation.lastpage","76"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Schmitt, Andrea"],["dc.contributor.author","Falkai, Peter Gaston"],["dc.contributor.author","Parlapani, Eleni"],["dc.date.accessioned","2019-07-10T08:13:30Z"],["dc.date.available","2019-07-10T08:13:30Z"],["dc.date.issued","2009"],["dc.description.abstract","Bei Schizophrenie finden sich Volumenverminderungen der grauen Substanz, besonders im Hippokampus und präfrontalen Kortex, sowie erweiterte Seitenventrikel. Die Diagnose dieser strukturellen Veränderungen sowie eine Hypergyrifizierung schon bei Ersterkrankung sprechen für das Vorliegen einer neuronalen Entwicklungsstörung, während andererseits die Volumenabnahme der grauen Substanz während der Erkrankungsdauer für einen zusätzlichen neurodegenerativen Prozess spricht. Klassische Anzeichen eines neurodegenerativen Prozesses wie die Abnahme der Neuronenzahl oder eine Astrogliose liegen bei der Erkrankung nicht gesichert vor. Dagegen gibt es Hinweise auf verminderte synaptische Proteine, die zu einer Konnektivitätsstörung in einem neuronalen Netzwerk führen können. Zusätzlich wurde in einer kürzlich veröffentlichten Postmortem- Studie eine verminderte Anzahl proliferierender Stammzellen im Gyrus dentatus des Hippokampus bei schizophrenen Patienten gefunden. Dies könnte eine zusätzliche Rolle bei der Bildung des Volumenverlusts des Hippokam- Aus der Abteilung für Psychiatrie und Psychotherapie, Universität Göttingen Korrespondenzadresse: Dr. med. Andrea Schmitt, Abteilung für Psychiatrie und Psychotherapie, Universität Göttingen, D-37075 Göttingen, von-Siebold-Straße 5; E-Mail: aschmit@gwdg.de pus spielen. Welche Wirkung dabei antipsychotisch wirksame Medikamente spielen, ist bislang unklar. Auch genetische Risikofaktoren können eine Rolle bei strukturellen Veränderungen im Gehirn spielen. Nachgewiesen wurde das für den Neuregulin-1-Risikohaplotyp (HAPICE), der bei schizophrenen Patienten und ihren gesunden Angehörigen mit einem kleineren Hippokampusvolumen assoziiert war. Weitere Erkenntnisse über Risikofaktoren der Schizophrenie könnten zukünftig spezifischere Therapieoptionen ermöglichen."],["dc.description.abstract","In schizophrenia, a reduced volume of gray matter, especially in the hippocampus and the prefrontal cortex, as well as enlarged lateral ventricles can be found. The diagnosis of these structural changes plus hypergyrification already in first-episode disease argues for the existence of a neuronal developmental disorder. On the other hand, the volume reduction of gray matter in the course of the illness additionally indicates progressing neurodegeneration. Indeed, classical signs of a neurodegenerative process such as reduction of neurons or astrogliosis cannot be securely identified for the disease, whereas there is evidence for reduced synaptic proteins which may lead to disturbed connectivity in a neuronal network. A recently published post-mortem study accessorily reports a reduced number of proliferating stem cells in the gyrus dentatus of the hippocampus in schizophrenic patients which might add to hippocampal volume loss. At present, the effects of antipsychotic medication remain unexplained. Genetic risk factors should also be considered as a possible cause for structural alterations in the brain. The neuregulin-1 risk haplotype (HAPICE), for example, has been proven to be associated with reduced hippocampus volume in schizophrenic patients and their healthy relatives. Further insights into schizophrenia risk factors could prospectively facilitate specific therapeutic options."],["dc.identifier.fs","535919"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6035"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/61264"],["dc.language.iso","de"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1608-1587"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Ist die Schizophrenie eine Störung der Synapto- oder Neurogenese?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]